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E-cadherinEpithelial to mesenchymal transition (EMT) is a process in which fully differentiated epithelial cells lose many of
their epithelial characteristics and adopt features typical of mesenchymal cells, thus allowing cells to become
migratory and invasive. EMT is a critical process in development and its role in cancer and fibrosis is becoming
increasingly recognised. It is also becoming apparent that EMT is not just restricted to embryonic development
and disease in adults, but in fact may be an important process for the maintenance and regeneration of adult
tissue architecture. While transforming growth factor-β (TGF-β) is considered a prototypic inducer of EMT,
relatively little is known about other signalling molecules that regulate EMT. Bone morphogenic proteins
(BMPs) are members of the TGF-β superfamily and 20 different human BMPs have been identified. Originally
named for their effects on bone, these proteins are now considered to be keymorphogenetic signals that orches-
trate tissue architecture throughout the body. BMP2, -4 and -7 are the best studied to date. There are disparate
reports of the roles of BMPs in EMT during development, cancer and fibrosis. Here, we present an overview
of this literature as well as the emerging role of EMT in tissue regeneration and the involvement of BMPs in
regulating this process.
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Epithelial tomesenchymal transition (EMT) is an orchestrated series
of events during which epithelial cells lose many of their epithelial-
specific characteristics and acquire features typical of mesenchymal
cells. Loss of the epithelial phenotype results from reduced expression
of specific epithelial proteins including junction-associated proteins,
such as ZO-1 and E-cadherin, and cytokeratins. The acquiredmesenchy-
mal phenotype is characterised by expression of cytoskeletal proteins
such as vimentin and α-smooth muscle actin (α-SMA), as well asaynooth, Maynooth, Co. Kildare,
McCormack),
ghts reserved.matrix metalloproteinases (MMPs). As a result of these phenotypic
changes, epithelial cells are released from the surrounding tissue and
become migratory and invasive [1]. It is well known that periods of
EMT are necessary during development but can also occur during fibro-
sis and tumour progression. More recently, EMT-like processes have
been described during tissue repair [2,3].
The phenotypic changes that occur to cells during EMT have been
extensively reviewed elsewhere [4–6]. During EMT, epithelial cells
reduce their expression of proteins involved in cell polarity and adhe-
sion while increasing their expression of various proteins that facilitate
increased cellmotility [7]. Loss of tight junctions and adherens junctions
is an early step in EMT and triggers cytoskeletal reorganisation and
alterations in the distribution of key molecules involved in cell polarity
(Fig. 1). Down-regulation of E-cadherin by several transcriptional re-
pressors is considered a key step in EMT. These repressors include
AD
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Fig. 1.During epithelial–mesenchymal transition (EMT), epithelial cells losemany of their
epithelial-specific characteristics and acquire features typical of mesenchymal cells.
(A) and (B) Loss of adherens junctions is an early step in EMT. Down-regulation of the
epithelial cell adhesion molecule E-cadherin by transcriptional repressors is considered
to be a key step. β-Catenin location switches from E-cadherin cell membrane complexes
to the cytoplasmic complexes which then translocate to the nucleus where they activate
mesenchymal-related genes such as α-smooth muscle actin and vimentin. (C) and (D) As
a result of the phenotypic changes that occur during EMT, epithelial cells are released from
the surrounding tissue and can become migratory and invasive.
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known as Slug), members of the basic Helix Loop Helix family (such
as Twist), and two ZEB factors (ZEB1 and ZEB2) [8]. These E-cadherin
repressors are thought to be key inducers of EMT that also drive wider
EMT ‘programmes’ by regulating both epithelial and mesenchymal genes,
including genes involved in extracellular matrix remodelling, cytoskeletal
reorganisation, and cell movements [9]. EMT is further characterised
by a switch in β-Catenin location and function. β-Catenin is released
from E-cadherin cell membrane complexes during EMT and interacts
with members of the lymphoid enhancer factor family of DNA-
binding proteins [10]. These active complexes then translocate to the
nucleus and activate target genes such as MMP-7,α-SMA and vimentin
[11,12].
Along with the loss of the classic epithelial phenotype, cells
undergoing EMT acquire several features of mesenchymal cells. In
contrast to epithelial cells, mesenchymal cells usually exhibit a
spindle-shaped morphology and display end-to-end polarity. While
mesenchymal cells typically exist without direct cell–cell contacts
or defined cell polarity, they do display distinct cell-extracellular
(ECM) interactions. Mesenchymal cells can contribute to ECM
remodelling by synthesizing and organising new components, as
well as degradation of existing ECM through the production ofMMPs [1]. In cells undergoing EMT, the cell cytoskeleton is reorganised
to facilitate cell migration and there is increased expression of mesen-
chymal cytoskeletal proteins including vimentin and α-SMA [13].
Vimentin is a major cytoskeletal protein of mesenchymal cells and has
been shown to induce changes in cell shape, motility and invasion dur-
ing EMT. Other markers used to define the mesenchymal phenotype in
EMT include fibroblast-specific protein-1 (FSP-1), desmin, fibronectin,
N-cadherin, MMPs and the transcription factors Snai1 and Snai2 [14].
Importantly, EMT is often reversible. Having migrated to their target
destinations, cells are thought to retain the ability to revert to their orig-
inal epithelial phenotype through a process known as mesenchymal to
epithelial transition (MET).
The phenotypic conversion that occurs during EMT requires molecu-
lar reprogramming of epithelial cells. Presumably, cells become mesen-
chymal and migratory in response to specific signalling factors during
EMT. The diverse molecular mechanisms that regulate EMT have been
the subject of many reports and reviews. Signal regulation is complex
withmanydifferent signalling pathways involved including transforming
growth factor-β (TGF-β), Wnt, Notch, Hedgehog and ILK signalling [15].
TGF-β1 is considered to be a prototypic inducer of EMT and has been
widely studied in this capacity [16]. Bone morphogenetic proteins
(BMPs) are members of the TGF-β superfamily. Named due to their
ability to induce bone formation, these morphogens in fact regulate
a wide range of processes including cell proliferation, differentiation,
apoptosis, morphogenesis and the patterning of various organs dur-
ing development [17,18]. BMP2, BMP4 and BMP7 are the most stud-
ied of the BMP ligands. BMP2 and BMP4 are 92% identical [19] and
are the mammalian homologues of Drosophila decapentaplegic pep-
tide (Dpp) [20]. BMP7 is a 35-kDa homodimeric protein and displays
a high degree of amino acid sequence homology with BMP-5 and
BMP-6. BMP ligands signal through heteromeric cell surface serine/
threonine kinase type I and II receptors. Upon ligation, receptormediat-
ed phosphorylation of intracellular proteins smad1, 5 and/or 8 occurs.
Partner protein smad4 then binds to the phosphorylated smads and
the resulting complex is transported to the nucleus where it modulates
transcription of specific genes [21]. Non-canonical BMP signalling also
occurs and involves Rho-like small GTPases, phosphatidylinositol 3-
kinase/Akt and various types of MAPK [22]. BMPs are being increasingly
examined for their roles as modulators of EMT. These roles are particu-
larly evident throughout embryonic development. There is also grow-
ing evidence of important roles for BMPs in EMT induction in fibrosis
as well as cancer development and progression. This review is aimed
at highlighting the key role played by BMPs in the regulation of EMT
in these various processes as well as the emerging role of EMT in tissue
regeneration and the involvement of BMPs therein.BMPs, EMT and embryonic development
EMT occurs during critical phases of embryonic development in
many animal species and has been previously reviewed [23]. Numerous
developmental events require this switch between epithelial and mes-
enchymal phenotypes including gastrulation, neural crest formation,
heart valve formation, nephrogenesis and myogenesis. The first inci-
dence occurs during gastrulation. The start of gastrulation, and the for-
mation of the three germ layers (ectoderm, mesoderm and endoderm),
aremarked by the formation of a transient structure called the primitive
streak. Ectodermal cells at the edge of the primitive streak undergo EMT
andmigrate (Fig. 2). These migrating cells either remain mesenchymal,
and give rise to the mesoderm, or undergo MET to form the endoderm
[24]. As development progresses, EMT occurs in cells of the ectoderm
resulting in neural crest cells. These mesenchymal neural crest cells,
having acquired a morphology that is appropriate for migration,
migrate through the developing embryo and settle in areas that are
involved in organ formation. Mesenchymal cells then participate in
the formation of epithelial organs through MET [25].
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Fig. 2.EMT is critical during embryonic development. A. Thefirst incidence of EMToccurs during gastrulation and leads to the formation of the three germ layers (ectoderm,mesodermand
endoderm). Ectodermal cells at the edge of the primitive streak undergo EMT and migrate. These cells internalise to generate mesoderm or undergo MET to form endoderm. Ectodermal
cells remain epithelial and contribute to the neural tube or the epidermis. B. EMT is also required during subsequent nervous system development to generate neural crest cells. Epithelial
cells in theneural tube undergo EMT, delaminate out of the dorsalmidline of the neural tube and becomemigratory neural crest cellswhich ultimately give rise to awide range of cell types
including cells of the sensory, sympathetic, and parasympathetic nervous systems, the pigment-containing cells of the epidermis and many of the skeletal and connective tissue compo-
nents of the head. BMP signalling plays a critical role in initial formation ofmesoderm during embryonic development, aswell as other stages including differentiation of neural crest cells.
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of EMT during embryonic development. Several studies using knockout
mice deficient for BMP ligands or Smad proteins have revealed that
BMP signalling is critical for correct regulation of EMTduring embryogen-
esis. Homozygous mutant BMP4 mice exhibit defects in gastrulation and
a failure to form themesoderm. Embryos die between E6.5 andE9.5 days,
implicating BMP4 as a critical morphogen in the patterning of the meso-
derm [26]. BMP2mutantmice also display abnormalities in the formation
of their extra-embryonic and embryonic mesodermal derivatives [27].
BmprIa-null mutant mice are unable to initiate gastrulation [28]. Chang
et al. have established that smad5 plays a pivotal role in certain embryon-
ic developmental programmes, specifically in ventrolateralmorphogene-
sis using smad5 deficient mice [29]. Additionally Smad1+/−:Smad5+/−
double heterozygous mutant embryos also display decreased mesoderm
in the mouse embryo [30].
Other studies have also established a link between BMP signalling
and EMT during embryonic development. High expression of BMP4
and BMP7 occurs in the epidermal ectoderm during the formation of
the neural crest [31]. The pattern of expression strongly suggests that
BMP signals derived from the epidermal ectoderm induce the formation
of neural crest cells. Increased expression of Snai2, a transcriptional
repressor of E-cadherin and an important inducer of EMT, also occurs
following stimulation of neural plate explants with BMP4 and BMP7.BMP signalling antagonists Noggin and Follistatin inhibit the induction
of neural crest cells by the epidermal ectoderm by up to 90%, demon-
strating that these BMP signals are crucial to the induction of neural
crest cells [32]. It has also been shown that Bmp2/4/7 genes are
expressed in the primitive streak along its A–P axis in chick embryos
[33].
The differentiation and migration of neural crest cells from the
neural tube involves EMT. The process includes the specification of a
premigratory cell fate, delamination from the epithelium, acquisition of
mesenchymal properties and finally migration [34]. BMP signalling has
been implicated in the specification of this neural cell fate with the dem-
onstration that BMP4/7 signalling is sufficient to activate amolecular pro-
gramme during neural crest differentiation and migration [35]. BMP
stimulation induced the expression of RhoB and Snai2 which were ob-
served in premigratory neural crest cells and transiently in migrating
neural crest cells. Snai2 expression is induced prior to that of RhoB during
the specification of premigratory neural crest cells. An increase in Snai2-
positive cells in neural plate explants exposed to BMP4 was observed,
suggesting possible EMT. In another study involving chick embryos, abla-
tion of Slug activity in vivo by antisense oligonucleotideswas also report-
ed to perturb neural crest cell differentiation [36].
Phosphorylated smad1/5/8, which is indicative of active BMP signal-
ling, is strongly expressed at the neural plate border, specifically in a
2859N. McCormack, S. O'Dea / Cellular Signalling 25 (2013) 2856–2862ring of cells located at the boundary between neural plate and
nonneural ectoderm [37]. Cells in this position at the neural plate
border give rise to neural crest cells through EMT, suggesting that
BMP signalling is involved in this process. The observation of phos-
phorylated Smad1 expression in ingressing cells of the primitive
streak prior to its formation is further suggestive of the involvement
of BMP signalling in EMT. Phosphorylated smad1 expression occurs
throughout the entire epiblast and is extinguished at the site of prim-
itive streak inhibition.
BMP2 has been shown to play a role in the development of the heart
during embryogenesis. Duringheart development, themyocardiumand
the endocardium of the atrioventricular (AV) canal undergo EMT, in-
vade the matrix-rich cardiac jelly and give rise to the endocardial cush-
ions. It has been shown that BMP2 promotes cardiac jelly formation and
signals directly to the AV endocardium to induce EMT [38]. AV cushion
defects and embryonic lethality occur in the absence of BMP2 in the AV
myocardium. Heart chamber and valve development is also dependent
on BMP signalling. The heart myocardium expresses BMP2 synchro-
nously with the development of mesenchymal cells specifically during
valve development. Consistent with this, conditional ablation of BMP2
in cardiac progenitor cells results in changes in cell fate. In the absence
of BMP2, there is a failure to induce production and deposition ofmatrix
at the heart-valve-forming region. This results in the inability of the en-
dothelium to swell, eventually leading to impaired endocardial cushion
development. In addition, it has been demonstrated that a BMP2mutant
endothelium is incapable of undergoing EMT [39].
Additional evidence implicating BMP signalling in the induction
of EMT has come from studies that utilised extracellular antagonists
of BMP signalling, Noggin and Gremlin-1. In the gastrula stage of em-
bryogenesis, the epiblast migrates towards the primitive streak and
ingresses through the primitive groove. By over expressing noggin in
chick embryos, it was found that inhibition of BMP signalling leads to
the arrest of ingressing cell movement by suppressing EMT [40]. Mice
deficient in Noggin also exhibited dysregulated EMT and constant in-
gression of cells. These results indicate that inhibition of BMP signalling
results in the suppression of EMT during chick and mouse embryonic
development. Gremlin-1 has been shown to play an important role in
regulation of BMP activity during the development of the lung, limb,
and kidney as well as during neural crest cell differentiation [41,42].
During lung development, Gremlin-1 interactswith theBMP4 precursor
protein during lung development and down regulates BMP4-mediated
signalling activity [43]. Gremlin also displays pattern-inducing proper-
ties during limb development [44], however a direct link between
gremlin and EMT during embryonic development has not yet been
identified.
Thus, the expression of BMP genes during embryonic development,
including their pattern of expression, time of expression and specifically
their expression during interactions between epithelial and migratory
cells indicates a central role in the induction of EMT during development.
BMP, EMT and cancer progression
A number of developmental processes appear to be recapitulated dur-
ing tumour progression towards a metastatic phenotype, including EMT
and cell invasion [45]. Furthermore, tumour cells are known to employ
several signalling pathways that are also critical to embryonic develop-
ment. It is therefore not surprising that a role for BMPs in the promotion
of tumour metastasis via EMT has been emerging in recent years. Studies
of several tumour types have shown that increased expression of BMPs
and their receptors by tumour cells is an important factor, and possibly
even a hallmark, in cancer progression [46,47]. It could be hypothesised
that BMP signalling in tumour cells leads to the expression of specific
transcription factors, including twist, Snai1 and Snai2, which activate an
EMT programme. This could lead to the emergence of mesenchymal-
like cells in the tumour cell population and could ultimately result in tis-
sue invasion and dissemination via the systemic circulation. Once distantorgans are reached, these mesenchymal-like tumour cells may reverse
back to an epithelial phenotype via MET. Subsequent proliferation
would lead to the establishment of a new tumour [48].
Increased BMP signalling has been implicated in the induction of EMT
in vitro in prostate, pancreatic and ovarian cancer and melanoma cells
[49–51]. BMP2, BMP4 and BMP7 have been shown to induce EMT in
the Panc-1 human pancreatic cancer cell line in vitro [52]. Treatment of
Panc-1 cells with these BMP ligands resulted in morphological changes
froma cobblestone appearance to a spindle-like phenotype and increased
invasiveness, indicative of EMT. All ligands also caused increased expres-
sion of Snai2 mRNA and decreased expression of E-cadherin protein and
mRNA. BMP2 and BMP4 increased invasiveness of cells throughmatrigel
and increased expression and activity of MMP-2 which has been shown
to be crucial in the dispersal stage of EMT. BMP2 has also been shown
to enhancemotility and invasion of gastric cancer cell lines and to induce
morphological changes resembling EMT [49]. BMP2-mediated reduction
in E-cadherin levels and increased Snai1 and vimentin levels further indi-
cate that BMP2-activated signalling is associated with EMT-mediated
morphologic changes in these cells. Similarly, BMP4 exposure induced
an EMT-like response in ovarian cancer cells in vitro that included elevat-
ed Snai1 and Snai2 mRNA and protein levels, reduced E-cadherin mRNA
and protein levels and α-SMA immunostaining resembling that of mes-
enchymal cells [53]. Using a wound assay to determine the effect of
BMP4 on cellmotility, BMP4was found to increase themotility of ovarian
cancer cells but not normal ovarian epithelial cells. Ovarian cancer cell re-
attachment was also increased in response to BMP4 stimulation while
noggin inhibited this response.
Literature regarding the involvement of BMP-7 in cancer is some-
what contradictory. Using both two-dimensional and ECM-embedded
cultures, BMP7-induced EMT in PC-3 prostate cancer cells [54]. In
contrast, in vivo studies have reported that BMP-7 preserves epithelial
phenotypes. In a study of prostate cancer metastasis, daily administra-
tion of BMP7 to nude mice previously injected with PC-3 cells resulted
in inhibition of growth of cancer cells in bone metastasis [55]. BMP7
has also been investigated in vivo in breast cancer growth andmetasta-
sis. Breast cancer growth and bone metastasis was inhibited in mice
following treatment with particularly high-doses of BMP7 [56]. These
contradictory reports of BMP7 effects suggest complex roles in tumour
progression, similar to those of TGF-β. TGF-beta can result in many
different fates depending on the cell type and stimulation involved.
TGF-beta causes epithelial cells to undergo growth arrest and apoptosis,
which may be beneficial in tumour progression. On the other hand it
can induce EMT andmediate fibroblast activation, whichmay be impli-
cated in promoting tumour progression and fibrotic diseases [57].
BMPs, EMT and fibrotic disease
The mechanisms underlying fibrotic disease remain poorly
understood. EMT, however, is known to contribute to the patho-
genesis of certain fibrotic diseases. It has been proposed that injury
can induce epithelial cells to undergo EMT, producing fibroblasts
and myofibroblasts that subsequently contribute to fibrosis in a
number of organs [58]. The switch of epithelial cells towards a mes-
enchymal phenotype is unfavourable and leads to the disruption of
epithelial layers and functions [4]. TGF-β1 expression is elevated
during fibrosis in several animal and human models [59]. However,
despite being members of the TGF-β superfamily, few studies have
addressed the role of BMPs in fibrosis. Given the role of BMPs in in-
ducing EMT during development, and the links between EMT and
fibrosis, we believe that BMP-mediated EMT processes may be in-
volved in fibrotic disease in adult organs.
To date, the members of the BMP family that have received most
attention for their potential roles in fibrosis are BMP7 and Gremlin.
However, these studies have sometimes produced seemingly contradic-
tory findings regarding these roles. BMP7 has in fact been considered an
anti-fibrotic ligand based on studies of rat kidney fibrosis. An in vivo
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strated a protective role of BMP7 [60,61]. Administration of recombi-
nant BMP7 during acute renal failure in rats preserved renal epithelial
cell morphology and improved renal function. BMP-7 also enhanced
recovery when infused into rats with ischemia-induced acute renal
failure [62]. In rat metanephric mesenchymal cells, inhibition of
BMP7 signalling using antisense oligonucleotides or anti-BMP-7 an-
tibodies blocked epithelial differentiation in a subpopulation of cells.
Thus BMP7 appears to play a role in induction and maintenance of
epithelial cell phenotypes. Studies on the mechanism of these anti-
fibrotic effects have suggested that BMP7 counteracts TGFβ-1-induced
EMT. In the kidney, EMT-induced accumulation of myofibroblasts is
considered to be a key determinant of renal fibrosis during chronic
renal injury [63]. Zeisberg et al. transfected renal distal tubular epitheli-
al cells with a plasmid expressing Smad5, to mimic the BMP7 signalling
pathway. This resulted in an increase in the activity of full length E-
cadherin promoter. They concluded that BMP7 may reverse TGF-β-
induced EMT by the induction of E-cadherin. E-cadherin is crucial for
maintaining an epithelial phenotype and the loss of E-cadherin is a hall-
mark of EMT. The protective role of BMP7 in renal fibrosis suggests a
crucial role of BMP signalling in regulating EMT. Subsequently, the
same group demonstrated that BMP7 could inhibit EMT in tubular epi-
thelial cells [64]. Administration of exogenous BMP7 to renal fibroblasts
resulted in decreased motility, increased expression of E-cadherin and
the formation of epithelial cell aggregates. BMP7 also decreased secretion
of type I collagen by adult renalfibroblast. All of these are hallmark stages
ofMET, hinting possible involvement of BMP7 in drivingMET thus restor-
ing the kidney damage. Given the role of BMP7 in antagonizing TGF-β
and suppressing EMT in renal epithelial cells it has been hypothesised
that induction of BMP7 may reduce injury-mediated EMT. Inhibitor of
DNA binding (Id) proteins have the ability to inhibit differentiation
of certain lineages and stimulate proliferation and these proteins are
major targets of BMP/Smad signalling [65]. Adenoviral gene transfer
of BMP7, Id2 and Id3 resulted in delayed injury-induced EMT in lens
epithelium of mice [66]. Expression patterns of α-smooth muscle
actin and collagens were decreased along with a reduction of Smad2
COOH-terminal phosphorylation.
However, while these studies indicate that BMP7 inhibits renal
fibrosis and TGFβ1-induced EMT, studies of its role in other tissues have
reported different results. In a mousemodel of bleomycin-induced fibro-
sis, systemically administered recombinant BMP7didnot affectfibrosis in
either the lung or skin and no effect on expression of pro-fibrotic genes
by lung fibroblasts was observed [67]. This suggests that BMP7 may
have diverse, even opposing, roles in different tissues.
The potential involvement of other BMP ligands in fibrosis has
received remarkably little attention to date and in vivo studies in partic-
ular are scarce. In vitro, BMP2 and BMP4 increase the expression of α-
SMA in cultured hepatic stellate cells (HSCs), the major cell type known
to be involved in the development of liver fibrosis [68]. This suggests
that, in contrast to BMP7 in the kidney, BMP2 and BMP4 may have
pro-fibrotic effects, via the induction of EMT, similar to TGF-β. Our
research group has also shown that BMP2, BMP4 and BMP7 induce
EMT-like responses in cultured mouse and in human airway epithelial
cells [3,69]. Cells exposed to these BMPs acquire a mesenchymal-like
morphology, have enhanced rates of cell migration and express elevat-
ed levels of α-SMA protein. Thus, BMPs may have pro-fibrotic effects
in vivo via the induction of EMT. These findings support a pro-fibrotic
effect of BMP7 in the lung, in contrast to its anti-fibrotic role in the
kidney.
Gremlin, an extracellular protein that negatively regulates BMP
activity, has been the focus of several studies investigating mechanisms
of fibrosis. A member of the CAN family of binding proteins, Gremlin
binds to BMP ligands 2, 4 and 7, preventing BMP receptor activation
[70]. Expression of Gremlin is significantly up-regulated in both pulmo-
nary and renal fibrosis [21,71]. Koli et al. reported increased expression
of Gremlin protein in mesenchymal cells in human IPF lungs comparedwith healthy lungs [72]. Using a stable A549 cell pool that overexpressed
gremlin, cell surface E-cadherinwas reduced and cellsweremore suscep-
tible to TGF-β1 induced EMT. They suggested a possible balance between
TGFβ-1, BMP signalling and EMT plays an important role in the transition
to a fibrotic phenotype. Gremlin mRNA levels were increased in lung
tissue in an asbestos-induced fibrotic mouse model, while levels of BMP
signalling were reduced demonstrated by reduced levels of Smad1/5/8
[21]. TGF-β signalling activity was increased in asbestos-treated normal
human bronchial/tracheal epithelial cells (NHBE cells), which resulted
in increased expression of Gremlin, as well as decreased BMP-signalling
indicated by reduced levels of Smad1/5/8. Over-expression of Gremlin
was shown to sensitize cultured epithelial cells to TGF-β-induced EMT
and blockade of TGF-β signalling inhibited asbestos-induced up-
regulation of Gremlin mRNA expression [21]. In contrast, systemic ad-
ministration of BMP7 has been shown to inhibit asbestos-induced fi-
brotic changes in vivo. The latter findings are consistent with previous
reports of BMP7-induced reversal of EMT and fibrosis following kidney
and liver injury [63,73].
Further evidence that Gremlin may be a mediator of EMT and that it
may play a pathogenic role in fibrotic diseases has come from a study of
patients with chronic allograft nephropathy (CAN). Increased expres-
sion of Gremlin, co-localizedwith TGF-β, was reported in these patients,
mainly in areas of tubulointerstitial fibrosis [74]. In the same tubules,
reduced expression levels of E-cadherin along with the increased
expression of both vimentin and α-SMA was also observed. Additional
in vitro work using human tubuloepithelial cells (HK2 cell line) found
elevated levels of Gremlin in cells undergoing TGF-β-induced EMT.
In a rodent model, Gremlin over-expression using adenoviral vectors
(AdGRE) induced transient pulmonary fibrosis [75]. Interestingly, in-
creased expression of FGF10 was observed in AdGRE-treated rats
compared with control animals, along with collagen deposition.
FGF10 has protective effects on epithelial cells, and has a pivotal
role in maintaining epithelial progenitor cell proliferation during de-
velopment. This suggests that Gremlin may play a dual role in the
lung under different conditions. The elevated levels of Gremlin ob-
served in fibrotic disease may in fact reflect a role for this protein re-
pair mechanisms.
In summary, EMT in adult tissues is increasingly recognised as
playing an important role in the development of fibrosis. BMP signalling
appears to play a role in the regulation of this EMT and thus may con-
tribute to the pathogenesis of certain fibrotic diseases. However, much
remains unknown regarding precise roles of the various BMP ligands,
and the wider BMP signalling network, in these processes.BMP, EMT and tissue regeneration
BMP signalling has been linked to key steps during regeneration in
several tissues. In an in vitro digit tip regeneration model, Msx1 mutant
mice display a regeneration defect. This defect can be rescued by BMP4
[76]. Furthermore, wild-type digit tip regeneration was inhibited with
Noggin, further implicating BMP signalling in this process. BMP signalling
has also been linked to tail regeneration in frog tadpoles and liver regen-
eration in zebrafish after partial hepatectomy [77]. The mechanism of
BMP-mediated regeneration in these models is not clear however. In ad-
dition to development, cancer and fibrosis, an EMT-like mechanismmay
occur during normal epithelial wound healing, although this concept has
beenmentioned only sporadically in the literature [78]. We are interest-
ed in this hypothesis and believe that BMPs are likely to play a role in
such a process. This has recently been reported in human skin wound
healing. A study using human skin tissues from acute wounds in the
phase of re-epithelialisation found that migrating epithelial cells in
woundmargins and deep epithelial ridges gainedmesenchymal features
such as vimentin and FSP1 expression [2]. In vitro, tumour necrosis
factor-α (TNF-α) induced expression of vimentin, FSP1, and matrix me-
talloproteinases in normal human skin and primary keratinocytes and
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Fig. 3.Proposed role of EMT innormal airway epithelialwound repair andfibrosis and regulation by BMPs. A. Uninjured, intact airway epithelium. B. Following airway injury and cell death,
surviving epithelial cells acquire an EMT-like phenotype in which E-cadherin is reduced and α-SMA is expressed in order to facilitate cell migration and wound repair. BMP4, BMP7 and
BMP2 are likely to play key roles in this process. Undernormal circumstances, this leads to restoration of the epithelium. C. In thepresence of chronic injury or inflammation, the EMTphase
is prolonged and permanent EMT and fibrosis results.
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TNF-α-induced EMT in human skin.
In the developing lung, BMP4 regulates branching morphogenesis
andmodulates proximal-to-distal differentiation of ciliated and secreto-
ry airway epithelial cells although themechanism involved is unknown
[15]. A role for BMP2 in lung development has not yet been established
and the role of BMPs in adult lungs has received relatively little atten-
tion to date. It has been proposed that signals critical to lung morpho-
genesis, such as BMP4, are also likely to be involved in regeneration
anddisease processes in adult lungs [16,17].Wehave been investigating
this hypothesis for several years. We have found that increased BMP
signalling is an early response in regenerating airway epithelial cells
in vivo following acute lung injury [79]. We believe that this signalling
plays a key role in driving the subsequent migration of epithelial
cells over the wounded airway. We have shown in vitro that BMP4 in-
duces an EMT-like response and enhances migration in the BEAS-2B
human lung cell line [69]. Furthermore, BMP2, BMP4 and BMP7 induce
a mesenchymal-like morphology in normal primary airway epithelial
cells (AECs) and enhance the rate of cell migration and increase α-
SMA protein expression in AECs during restitution of a disrupted
epithelium [3]. Others have also shown that TGF-β1 induces EMT in pri-
mary AECs and that EMTmay be enhanced in asthmatic airways [80,81].
These findings lead us to hypothesise that BMP signalling is a key
initiator of airway epithelial cell migration after injury and that the mi-
gration process involves a transient EMT-like phase. We suggest that
following re-epithelialisation of a damaged airway epithelium, amesen-
chymal–epithelial transition (MET) may occur to restore the differenti-
ated epithelium. Furthermorewe suggest that a paradigm in the fibrosis
field could be adjusted also. It has been proposed that severe/chronic in-
jury and/or inflammation in the airways and other tissues causesepithelial cells to undergo EMT that contributes to fibrosis [82,83]. In-
stead, we suggest that chronic/severe injury or inflammation may not
directly induce EMT in epithelial cells to cause fibrosis. Rather, EMT oc-
curs as a normal repair process during the initial injury but fails to re-
verse via MET because of the chronic injury conditions, resulting in a
permanent EMT that leads to airway fibrosis. This is consistent with
the view of fibrosis as a permanent injury state, but with the difference
that the initial EMT event is a normal injury response (Fig. 3). The prob-
lem may arise when the subsequent MET is delayed or inhibited by
persistent injury/inflammation. If this is correct, strategies to treatfibro-
sis could address encouragement ofMET. Further studies are required to
fully characterise the extent towhich EMT occurs in AECs duringwound
healing and to determine whether MET occurs once re-epithelialisation
is complete.
Summary
In summary, evidence is increasing that the BMP subfamily of
morphogens plays a key role in the regulation of EMT during normal
processes such as development, and also regeneration in adult tissues,
as well as diseases including cancer and fibrosis.
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